Valsartan Tablet shortage
To Be Discontinued 4 presentations · 1 manufacturers · first FDA posting 2025-11-19 · last update 2025-11-19
Manufacturers: Mylan Pharmaceuticals Inc., a Viatris Company
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Valsartan, Tablet, 40 mg (NDC 0378-5807-93) | Mylan Pharmaceuticals Inc., a Viatris Company | To Be Discontinued | — | A business decision was made to discontinue manufacture of the drug. | Posted 11/19/2025 Updated 11/19/2025 Discontinued 11/19/2025 |
| Valsartan, Tablet, 80 mg (NDC 0378-5813-77) | Mylan Pharmaceuticals Inc., a Viatris Company | To Be Discontinued | — | A business decision was made to discontinue manufacture of the drug. | Posted 11/19/2025 Updated 11/19/2025 Discontinued 11/19/2025 |
| Valsartan, Tablet, 160 mg (NDC 0378-5814-77) | Mylan Pharmaceuticals Inc., a Viatris Company | To Be Discontinued | — | A business decision was made to discontinue manufacture of the drug. | Posted 11/19/2025 Updated 11/19/2025 Discontinued 11/19/2025 |
| Valsartan, Tablet, 320 mg (NDC 0378-5815-77) | Mylan Pharmaceuticals Inc., a Viatris Company | To Be Discontinued | — | A business decision was made to discontinue manufacture of the drug. | Posted 11/19/2025 Updated 11/19/2025 Discontinued 11/19/2025 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)